AbCellera (ABCL) reports potency of bamlanivimab against SARS-CoV-2

AbCellera (ABCL) reports potency of bamlanivimab against SARS-CoV-2

(vitag.Init = window.vitag.Init || []).push(function () { viAPItag.display(“vi_1088641796”) })

AbCellera reported the potency of bamlanivimab (LY-CoV555) in neutralizing SARS-CoV-2 in one study. Credit: AbCellera Biologics.

AbCellera (ABCL) reported that bamlanivimab (LY-CoV555) demonstrated high potency in neutralizing SARS-CoV-2 by uniquely binding confirmations both up and down the binding domain to peak receptor (RBD) in a preclinical study.

Developed from the partnership between Eli Lilly and Company and AbCellera, bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the SARS-CoV-2 spike protein.

In the study, non-human primates were treated prophylactically with 1 mg / kg, 2.5 mg / kg, 15 mg / kg and 50 mg / kg of bamlanivimab 24 hours before becoming infected with the virus.

Results generated in a preclinical model also showed troublesome critical interactions with the cellular angiotensin-converting enzyme 2 (ACE2) receptor, which is vital for viral entry.

In addition, prophylactic treatment with bamlanivimab resulted in a significant reduction in viral load and replication in the upper and lower respiratory tract upon exposure to SARS-CoV-2, indicating its potential to reduce excretion and viral transmission.

A dose of 2.5 mg / kg of bamlanivimab and higher serum concentrations were associated with increased protection in this model.

AbCellera Scientific Director Bo Barnhart said: “The unique ability of bamlanivimab to bind to the spike protein in the high and low position may underlie the greater neutralizing power of bamlanivimab compared to other antibody.

“These preclinical data show that modest doses of bamlanivimab provided protection against SARS-CoV-2 infection, which has since been confirmed in clinical trials to protect residents and staff of long-term care facilities. and retirement homes.

Within 90 days, bamlanivimab went from first screening to clinical testing and is the first mAb specifically developed against SARS-CoV-2 to obtain Emergency Use Clearance (EUA) from the Food and Drug United States Administration (FDA).

So far, the antibody has been used in the treatment of approximately 400,000 patients with high-risk Covid-19 in the United States alone and is authorized in more than 15 countries.

In clinical trials, prophylactic use of bamlanivimab reduced hospitalization by 70% in high-risk patients with early-onset Covid-19 and decreased the risk of contracting the disease by up to 80% in residential residents. nursing.

s.parentNode.insertBefore(t,s)}(window, document,’script’,
fbq(‘init’, ‘1501063880195208’);
fbq(‘track’, ‘PageView’);

(vitag.Init = window.vitag.Init || []).push(function () { viAPItag.display(“vi_1088641796”) })


Please enter your comment!
Please enter your name here